From June 24 to 26, 2025, the 23rd Convention on Pharmaceutical Ingredients China (CPHI China 2025) was grandly held at the Shanghai New International Expo Centre. As the premier event in the global pharmaceutical industry, this exhibition attracted over 3500 exhibitors and over 100,000 professional visitors from more than 150 countries and regions.

As a leading enterprise in China's blood product industry, Grand Shuyang Life Sciences (Chengdu) Co., Ltd. has participated in the CPHI exhibition for consecutive years and demonstrated the outstanding capabilities of Chinese blood product companies to the global market. The Company showcased core products such as human albumin, human immunoglobulin for intravenous injection, and human rabies immunoglobulin, which attracted professional clients from multiple countries in Asia Pacific, the Middle East, Africa, and Latin America for in-depth cooperation discussions.

The Company's exhibition director stated: "Participating in international exhibitions such as CPHI is a key component of our globalization strategy. We strive not only to showcase China's intelligent manufacturing to the world but also to gain global recognition for China's quality." Grand Shuyang's products have entered markets in multiple countries and regions, and its overseas business has maintained high-speed growth for consecutive years.

Looking ahead, Grand Shuyang will continue to focus on patient needs, deepen its presence in the blood product field, optimize its product portfolio, and actively expand international markets. Aiming to become an "international high-quality service provider across the entire blood product chain", the Company will advance the global presence of Chinese blood products and provide products and services of higher quality and standards to patients worldwide.